Larimar Therapeutics (LRMR) Cash & Equivalents Growth (1y) (2014 - 2026)
Powered by 
Analysis
Larimar Therapeutics (LRMR) Cash & Equivalents Growth (1y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 74.25% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -38.20% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 23.56% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 23.05% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 71.81% |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 34.71% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 53.39% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -53.42% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -57.58% |
| 10 | Larimar Therapeutics | 397.87 Mn | 241.60 Mn | - | 350.22% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 350.22% |
| Dec 31, 2025 | 157.13% |
| Sep 30, 2025 | 157.05% |
| Jun 30, 2025 | -36.28% |
| Mar 31, 2025 | -80.82% |
| Dec 31, 2024 | 24.18% |
| Sep 30, 2024 | -9.44% |
| Jun 30, 2024 | -65.74% |
| Mar 31, 2024 | -1.25% |
| Dec 31, 2023 | -0.28% |
| Sep 30, 2023 | -55.00% |
| Jun 30, 2023 | 377.91% |
| Mar 31, 2023 | 78.15% |
| Dec 31, 2022 | -61.73% |
| Sep 30, 2022 | 10.32% |
| Jun 30, 2022 | -72.06% |
| Mar 31, 2022 | 0.65% |
| Dec 31, 2021 | 2.86% |
| Sep 30, 2021 | -23.01% |
| Jun 30, 2021 | -37.31% |